Precision treatment for human epidermal growth factor receptor 2-amplified advanced rectal cancer: A case report

Figure 1 Management and treatment protocol for a patient with advanced rectal cancer. FOLFOX: Oxaliplatin plus 5-fluorouracil; FOLFIRI: Irinotecan plus 5-fluorouracil; PD: Progressive disease; PR: Partial response; OXA: Oxaliplatin.

Figure 2 Computed tomography imaging of the patient during therapy. A-D: Initial liver and lung metastases after chemotherapy were revealed by computed tomography on December 1, 2021; E-H: Computed tomography imaging on February 24, 2022, demonstrated reduced metastases in the liver and lung following two months of targeted therapy; I-L: Computed tomography imaging on May 25, 2022, showed a marked reduction in the size of lung lesions following five months of targeted therapy with programmed death 1 antibody and pyrotinib.

Figure 3 The change in carcinoembryonic antigen levels during treatment in a patient with advanced rectal cancer. CEA: Carcinoembryonic antigen.